The combined positive score (CPS), which includes PD-L1 staining in tumor cells, macrophages, and lymphocytes, has been shown to better predict immunotherapy response than the tumor proportion score (TPS), which only reflects PD-L1 expression in tumor cells. Here, CD274 is linked to neoplasm.